Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

21. Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men (PubMed)

Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men Experimentally controlled studies of estrogenic regulation of lipid measures and inflammatory cytokines in men are rare.To delineate the effect of estradiol (E2) on lipids and inflammatory markers.This was a placebo-controlled, single-masked, prospectively randomized study comprising experimentally degarelix-downregulated healthy men [n = 74; age 65 years (range, 57 to 77)] assigned to four (...) treatment groups: (1) IM saline and oral placebo; (2) IM testosterone and oral placebo; (3) IM testosterone and oral anastrozole (aromatase inhibitor); and (4) IM testosterone, oral anastrozole, and transdermal E2 for 22 (±1) days.Mean mass spectrometry-quantified serum E2 concentrations ranged from 1.2 to 82 pg/mL in the four treatment groups. E2 extremes did not alter total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol (HDL-C) , non-HDL-C

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

22. Evaluation and Management of Testosterone Deficiency

Evaluation and Management of Testosterone Deficiency 1 Executive Summary Testosterone testing and prescriptions have nearly tripled in recent years; however, it is clear from clinical practice that there are many men using testosterone without a clear indication. 1-3 Some studies estimate that up to 25% of men who receive testosterone therapy do not have their testosterone tested prior to initiation of treatment. 2, 3 Of men who are treated with testosterone, nearly half do not have (...) their testosterone levels checked after therapy commences. 2, 3 While up to a third of men who are placed on testosterone therapy do not meet the criteria to be diagnosed as testosterone deficient, 2, 3 there are a large percentage of men in need of testosterone therapy who fail to receive it due to clinician concerns, mainly surrounding prostate cancer development and cardiovascular events, although current evidence fails to definitively support these concerns. Given the clinical and commercial testosterone

2018 American Urological Association

23. Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements (PubMed)

Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements A perimenopausal woman presented with palpitations, hirsutism, and inability to lose weight. Laboratory tests revealed an unusual endocrine hormonal profile including pituitary hormones (TSH, ACTH, and prolactin) below reference intervals and gonadal (testosterone) and adrenal (cortisol) hormones above reference intervals. Ultimately, after a comprehensive workup including a scheduled surgical procedure, abnormal (...) , but also in tests for gonadal steroids, adrenal, and pituitary hormones. Falsely high as well as falsely low results can be ascribed to biotin. Competitive immunoassays (Fig. 1A)- in this case, tests used initially for serum cortisol and testosterone- can demonstrate falsely high results. Interference falsely lowers the immunometric "sandwich" immunoassay (Fig. 1B)-in this case, TSH. Biotin effect on our patient's endocrine testing led to decidedly abnormal findings, unnecessary medical referrals

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

24. Testosterone Therapy in Men with Hypogonadism

Testosterone Therapy in Men with Hypogonadism We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search (...) input Article Navigation Close mobile search navigation Article navigation May 2018 Article Contents Article Navigation Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline Shalender Bhasin Brigham and Women’s Hospital, Boston, Massachusetts Correspondence: Shalender Bhasin, MB, BS, Director, Research Program in Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women’s Hospital, Boston, MA 02115. E

Full Text available with Trip Pro

2018 The Endocrine Society

25. Association of serum testosterone and dehydroepiandrosterone sulfate with rheumatoid arthritis: a case control study (PubMed)

Association of serum testosterone and dehydroepiandrosterone sulfate with rheumatoid arthritis: a case control study It is supposed that hypoandrogenism may be involved in the pathogenesis of rheumatoid arthritis (RA). Testosterone and dehydroepiandrosterone sulfate (DHEAs) levels decrease in body fluids of patients with RA.The aim of this study was to determine the association of serum testosterone and DHEAs with RA.This case-control study was conducted on 59 patients with RA and 61 healthy (...) gender- and age-matched controls at Qazvin University of Medical Sciences, Qazvin, Iran, in 2014. Serum free testosterone and DHEAs levels were measured and compared between two groups. Serum testosterone levels lower than 0.029 ng/ml in females and 2.49 ng/ml in males were considered as abnormal. DHEAs levels lower than 18.9 μg/dl in females and 88.9 μg/dl in males were considered as abnormal. Data were analyzed using independent sample T-test, Chi-square test, and logistic regression analysis

Full Text available with Trip Pro

2018 Electronic physician

26. Testosterone and All-Cause Mortality in Older Men: The Role of Metabolic Syndrome (PubMed)

Testosterone and All-Cause Mortality in Older Men: The Role of Metabolic Syndrome Previous studies have shown controversial results about the role of testosterone in all-cause mortality in elderly men. We hypothesized that metabolic syndrome (MetS) could partly explain this discrepancy. We therefore examined the association of all-cause mortality with total and bioavailable testosterone, taking into account the MetS. We used data from the Three-City Cohort (3C) study with 12-year follow-up (...) . The 3C study included 3650 men aged >65 years in three French cities. Hormone was measured in a random subsample of 444 men, and MetS was determined as stated by the International Diabetes Federation criteria. We used inverse-probability-weighted Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Of 444 men included in the analysis, 106 (23.9%) had MetS at baseline, and 166 died over the follow-up. There was a significant interaction between testosterone level

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

27. Bioavailable Testosterone Is Positively Associated With Bone Mineral Density in Male Kidney Transplantation Candidates (PubMed)

Bioavailable Testosterone Is Positively Associated With Bone Mineral Density in Male Kidney Transplantation Candidates Low levels of sex hormones are common in patients with chronic kidney disease (CKD) and may be a contributing factor to bone fragility. We investigated associations between levels of sex hormones and bone mineral density (BMD) in adult kidney transplantation candidates.Volumetric BMD of spine and hip were measured by computed tomography. Parathyroid hormone (PTH), testosterone

Full Text available with Trip Pro

2018 Kidney international reports

28. Associations Between Low Serum Testosterone and All-Cause Mortality and Infection-Related Hospitalization in Male Hemodialysis Patients: A Prospective Cohort Study (PubMed)

Associations Between Low Serum Testosterone and All-Cause Mortality and Infection-Related Hospitalization in Male Hemodialysis Patients: A Prospective Cohort Study Infectious diseases are the second highest cause of death in patients on dialysis. In addition, testosterone deficiency or hypogonadism is prevalent in dialysis patients. However, to our knowledge, no studies have investigated the association between testosterone levels and infectious events. We aimed to evaluate whether serum (...) testosterone levels are associated with infection-related hospitalization in male hemodialysis patients in a prospective cohort study.We divided the study population into 3 groups based on serum testosterone levels. Associations between testosterone levels and clinical outcomes of infection-related hospitalization, all-cause mortality, and cardiovascular disease (CVD) events were analyzed using the Cox proportional hazard model.Nine hundred two male patients were enrolled and followed up for a median

Full Text available with Trip Pro

2017 Kidney international reports

29. Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 (PubMed)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 We reviewed testosterone changes for patients who were treated with radiation therapy (RT) alone on NRG oncology RTOG 9408.Patients (T1b-T2b, prostate-specific antigen <20 ng/mL) were randomized between RT alone and RT plus 4 months of androgen ablation. Serum testosterone (ST) levels were investigated at enrollment, RT completion, and the first follow-up 3 months after RT (...) . The Wilcoxon signed rank test was used to compare pre- and post-treatment ST levels in patients who were randomized to the RT-alone arm.Of 2028 patients enrolled, 992 patients were randomized to receive RT alone and 917 (92.4%) had baseline ST values available and completed RT. Of these 917 patients, immediate and 3-month post-RT testosterone levels were available for 447 and 373 patients, respectively. Excluding 2 patients who received hormonal therapy off protocol after RT, 447 and 371 patients

Full Text available with Trip Pro

2017 Advances in radiation oncology

30. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone (PubMed)

Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone Intramuscular (IM) testosterone is the most common modality for testosterone therapy of both male hypogonadism and female-to-male (FTM) gender transition. However, IM injections can be painful and often are not self-administered by the patient. The objective of this study was to further characterize subcutaneous (SC) administration of testosterone as an effective and safe (...) alternative to IM injections by evaluating the pharmacodynamics of serum total and free testosterone concentrations between weekly testosterone injections.Eleven FTM transgender patients already receiving weekly SC testosterone cypionate with documented therapeutic levels prior to enrollment had free and total serum testosterone levels measured at eight different time points during a 1-week dosing interval.Mean levels of total and free testosterone were stable and remained well within the normal range

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

31. Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer Purpose The association between exposure to testosterone replacement therapy (TRT) and prostate cancer risk is controversial. The objective was to examine this association through nationwide, population-based registry data. Methods We performed a nested case-control study in the National Prostate Cancer Register of Sweden, which includes all 38,570 prostate cancer cases diagnosed from 2009 to 2012, and 192,838

Full Text available with Trip Pro

2017 EvidenceUpdates

32. Genetics of Sex Hormone-Binding Globulin and Testosterone Levels in Fertile and Infertile Men of Reproductive Age (PubMed)

Genetics of Sex Hormone-Binding Globulin and Testosterone Levels in Fertile and Infertile Men of Reproductive Age Testosterone (T) is a central androgenic hormone, and sex hormone-binding globulin (SHBG) is the major determinant of its bioactivity. There are no acknowledged genetic variants with clear-cut clinical implications, modulating T levels in men.To confirm genetic associations of top loci (SHBG, GCKR, SLCO1B1, and JMJD1C) from genome-wide association (GWA) studies for serum SHBG

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

33. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. (PubMed)

Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time.To investigate associations between televised DTCA and testosterone testing and initiation in the United States.Ecologic study conducted in designated market areas (DMAs (...) ) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations.Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs.(1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection

Full Text available with Trip Pro

2017 JAMA

34. The putative effects of D-Aspartic acid on blood testosterone levels: A systematic review. (PubMed)

The putative effects of D-Aspartic acid on blood testosterone levels: A systematic review. D-Aspartic acid (D-Asp) is in invertebrate and vertebrate neuroendocrine tissues, where it carries out important physiological functions. Recently, it has been reported that D-Asp is involved in the synthesis and release of testosterone and is assumed can be used as a testosterone booster for infertile men, and by athletes to increase muscle mass and strength.The aim of this review is to summarize (...) available evidence related to the effects of D-Asp on serum testosterone levels.We conducted a systematic review of all type studies, which evaluated the effect of the D-Asp on blood testosterone including published papers until October 2015, using PubMed, ISI Web of Science, ProQuest and Scopus database.With 396 retrieved records, 23 animal studies and 4 human studies were included. In vivo and in vitro animal studies revealed the effect of D-Asp depending on species, sex and organ-specific. Our

Full Text available with Trip Pro

2017 International journal of reproductive biomedicine (Yazd, Iran)

35. Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet (PubMed)

Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet In obese men with lowered testosterone levels, testosterone treatment augments diet-associated loss of body fat.We hypothesized that testosterone treatment modulates circulating concentrations of hormonal mediators of fat mass and energy homeostasis in obese men undergoing a weight loss program.Prespecified secondary analysis of a randomized, double-blind, placebo-controlled trial.Tertiary (...) referral center.Obese men (body mass index ≥30 kg/m2) with a repeated total testosterone level ≤12 nmol/L.One hundred participants mean age 53 years (interquartile range 47 to 60 years) receiving 10 weeks of a very low-energy diet followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (cases, n = 49) or matching placebo (controls, n = 51). Eighty-two men completed the study.Between-group differences in leptin, adiponectin

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

36. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. (PubMed)

Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. Recent studies have yielded conflicting results as to whether testosterone treatment increases cardiovascular risk.To test the hypothesis that testosterone treatment of older men with low testosterone slows progression of noncalcified coronary artery plaque volume.Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 (...) years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism who were enrolled in the Testosterone Trials between June 24, 2010, and June 9, 2014.Testosterone gel, with the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months.The primary outcome was noncalcified coronary artery plaque volume, as determined by coronary computed

Full Text available with Trip Pro

2017 JAMA

37. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. (PubMed)

Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions.To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI).The Testosterone Trials (TTrials) were 7 trials (...) to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n = 394) or placebo (n = 394). A subgroup of 493 men met criteria for AAMI based on baseline subjective

Full Text available with Trip Pro

2017 JAMA

38. Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines

Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Published on: February 9, 2017 Project Number: RA0892-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of testosterone for patients with depression? What is the clinical effectiveness of testosterone for patients with post-traumatic stress disorder? What is the clinical effectiveness of testosterone for patients with fibromyalgia? What are the evidence-based guidelines for the use of testosterone for patients with depression, PTSD, or fibromyalgia? Key Message Two systematic reviews, two randomized controlled trials

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

39. Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) (PubMed)

Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) Measurement of salivary testosterone (Sal-T) to assess androgen status offers important potential advantages in epidemiological research. The utility of the method depends on the interpretation of the results against robustly determined population distributions, which are currently lacking.To determine age-specific Sal-T

Full Text available with Trip Pro

2017 Journal of the Endocrine Society